Indications
Trixeo Aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.
Composition
- Active substance
- formoterol fumarate dihydrate, glycopyrronium bromide, Budesonide
- International name (INN)
- formoterol;glycopyrronium bromide;budesonide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Trixeo Aerosphere
- Active substance
- formoterol fumarate dihydrate, glycopyrronium bromide, Budesonide
- ATC code
- R03AL
- Group
- Respiratory system